Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
Leuk. Lymphoma., Dec (2012)
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
J. Clin. Oncol., Dec;30(35):4323-9 (2012)
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Blood., Nov;120(19):3898-905 (2012)
Pretransplant MRD: the light is yellow, not red.
Blood., Jul;120(2):244-6 (2012)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Blood., Aug;120(7):1398-408 (2012)
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Leukemia., Jun (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Blood., Mar;119(11):2657-64 (2012)
Chronic myelogenous leukemia.
J Natl Compr Canc Netw., Jan;10(1):64-110 (2012)
IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.
Cancer Cell., Nov;20(5):661-73 (2011)
The biology of chronic myelogenous leukemia progression: who, what, where, and why?
Hematol. Oncol. Clin. North Am., Oct;25(5):967-80, v (2011)
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
Clin. Cancer Res., Nov;17(21):6812-21 (2011)
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
Blood., Oct;118(17):4561-6 (2011)
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
Am. J. Hematol., Sep;86(9):811-9 (2011)
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
Blood., Sep;118(13):3634-44 (2011)
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Cancer., Jan;118(2):300-11 (2012)
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
J Natl Compr Canc Netw., Feb;9 Suppl 2:S1-25 (2011)
Chronic myeloid leukemia 2010: where are we now and where can we go?
Hematology Am Soc Hematol Educ Program., 2010:122-8 (2010)
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Br. J. Haematol., Dec;151(5):430-4 (2010)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood., Jan;117(4):1141-5 (2011)
Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?
Am. J. Hematol., Nov;85(11):856-62 (2010)